HK1157337A1 - - Google Patents

Info

Publication number
HK1157337A1
HK1157337A1 HK11111670.1A HK11111670A HK1157337A1 HK 1157337 A1 HK1157337 A1 HK 1157337A1 HK 11111670 A HK11111670 A HK 11111670A HK 1157337 A1 HK1157337 A1 HK 1157337A1
Authority
HK
Hong Kong
Prior art keywords
cancer
therapy
compounds
useful
pharmaceutically acceptable
Prior art date
Application number
HK11111670.1A
Other languages
English (en)
Inventor
Maurizio Pulici
Fabio Zuccotto
Alessandra Badari
Stefano Nuvoloni
Giovanni Cervi
Gabriella Traquandi
Sonia Biondaro
Paolo Trifiro'
Chiara Marchionni
Michele Modugno
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1157337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1157337A1 publication Critical patent/HK1157337A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11111670.1A 2008-07-24 2011-10-28 HK1157337A1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1157337A1 true HK1157337A1 (xx) 2012-06-29

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11111670.1A HK1157337A1 (xx) 2008-07-24 2011-10-28

Country Status (20)

Country Link
US (2) US8541575B2 (xx)
EP (1) EP2324008B1 (xx)
JP (1) JP5385382B2 (xx)
CN (1) CN102105459B (xx)
AT (1) ATE557015T1 (xx)
AU (1) AU2009273197B2 (xx)
BR (1) BRPI0916356B1 (xx)
CA (1) CA2731146C (xx)
CL (1) CL2011000124A1 (xx)
CY (1) CY1117667T1 (xx)
DK (1) DK2324008T3 (xx)
EA (1) EA019722B1 (xx)
ES (1) ES2386408T3 (xx)
HK (1) HK1157337A1 (xx)
HR (1) HRP20120577T1 (xx)
MX (1) MX2011000738A (xx)
PL (1) PL2324008T3 (xx)
PT (1) PT2324008E (xx)
SI (1) SI2324008T1 (xx)
WO (1) WO2010010154A1 (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
UA103319C2 (xx) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола
EA019722B1 (ru) * 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP2528909B1 (en) * 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
KR20130048293A (ko) * 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
EP2601185B1 (en) * 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN103562202B (zh) * 2011-01-25 2016-09-14 密执安大学评议会 Bcl-2/bcl-xl抑制剂和使用它们的治疗方法
CN103403002B (zh) 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
MX355016B (es) 2011-10-06 2018-04-02 Bayer Ip Gmbh Heterociclilpiri(mi)dinilpirazoles como fungicidas.
EP2763993B1 (en) 2011-10-06 2017-04-19 Bayer Intellectual Property GmbH Heterocyclylpyri(mi)dinylpyrazole
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
AP2015008381A0 (en) 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
CN110305162A (zh) 2013-01-16 2019-10-08 密歇根大学董事会 BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
BR112018001469B1 (pt) * 2015-08-03 2023-04-25 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e uso de um composto
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
CN114591242A (zh) 2015-12-16 2022-06-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
RU2759669C2 (ru) 2016-06-03 2021-11-16 Аррэй Байофарма Инк. Фармацевтические комбинации
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
WO2019081485A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019081477A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020087024A1 (en) * 2018-10-26 2020-04-30 Arrien Pharmaceuticals Llc Pyrazolyl compounds and methods of use thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
AU2020287208A1 (en) 2019-06-03 2022-01-06 Bayer Aktiengesellschaft 1-phenyl-5-azinyl pyrazolyl-3-oxyalkyl acids and their use for controlling undesired plant growth
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
KR102323820B1 (ko) * 2019-10-31 2021-11-08 한국화학연구원 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN112979613B (zh) * 2019-12-16 2022-04-26 四川大学华西医院 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
EP4075979A1 (de) 2019-12-19 2022-10-26 Bayer Aktiengesellschaft 1,5-diphenylpyrazolyl-3-oxyalkylsäuren und 1-phenyl-5-thienylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
BR112022012674A2 (pt) 2020-01-31 2022-09-06 Bayer Ag Derivados de ácido [(1,4,5-trissubstituído-1h-pirazol-3-il)sulfanil]acético e sais dos mesmos e uso dos mesmos como ingredientes herbicidas ativos
WO2021202900A1 (en) * 2020-04-02 2021-10-07 Plexxikon Inc. 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
WO2021219527A1 (de) 2020-04-29 2021-11-04 Bayer Aktiengesellschaft 1-pyrazinylpyrazolyl-3-oxyalkylsäuren sowie deren derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
CN116368129A (zh) 2020-10-23 2023-06-30 拜耳公司 1-(吡啶基)-5-吖嗪基吡唑衍生物及其用于控制有害的植物生长的用途
TW202233607A (zh) * 2020-10-30 2022-09-01 瑞士商諾華公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之新結晶形式
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022296784A1 (en) 2021-06-25 2024-01-18 Bayer Aktiengesellschaft (1,4,5-trisubstituted-1h-pyrazole-3-yl)oxy-2-alkoxy alkyl acids and their derivatives, their salts and their use as herbicidal agents
WO2023091873A1 (en) * 2021-11-19 2023-05-25 The Board Of Trustees Of The University Of Illinois Gram-negative specific antibiotics sparing effect on gut microbiome
CN118632626A (zh) 2021-12-01 2024-09-10 拜耳公司 (1,4,5-三取代-1h-吡唑-3-基)氧-2-烷氧基硫代烷基酸及其衍生物、其盐及其作为除草活性剂的用途
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024078871A1 (de) 2022-10-14 2024-04-18 Bayer Aktiengesellschaft 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GEP20033053B (en) 1997-05-22 2003-08-25 Searle & Co Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
AU2005205118B2 (en) * 2004-01-09 2009-02-26 Novartis Ag Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
MX2009003456A (es) * 2006-10-02 2009-04-14 Irm Llc Compuestos y composiciones como inhibidores de proteina cinasa.
EA019722B1 (ru) * 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EP2528909B1 (en) * 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents

Also Published As

Publication number Publication date
CL2011000124A1 (es) 2011-05-06
EP2324008B1 (en) 2012-05-09
EA201170249A1 (ru) 2011-10-31
EA019722B1 (ru) 2014-05-30
US8541575B2 (en) 2013-09-24
AU2009273197B2 (en) 2014-01-16
CA2731146A1 (en) 2010-01-28
BRPI0916356A2 (xx) 2018-08-21
US20140005150A1 (en) 2014-01-02
CA2731146C (en) 2016-05-03
CN102105459B (zh) 2014-09-10
AU2009273197A2 (en) 2011-03-10
CY1117667T1 (el) 2017-05-17
US8946250B2 (en) 2015-02-03
AU2009273197A1 (en) 2010-01-28
ES2386408T3 (es) 2012-08-20
WO2010010154A1 (en) 2010-01-28
HRP20120577T1 (hr) 2012-08-31
PL2324008T3 (pl) 2012-09-28
MX2011000738A (es) 2011-02-23
US20110144068A1 (en) 2011-06-16
JP2011528698A (ja) 2011-11-24
DK2324008T3 (da) 2012-07-23
JP5385382B2 (ja) 2014-01-08
EP2324008A1 (en) 2011-05-25
PT2324008E (pt) 2012-06-25
SI2324008T1 (sl) 2012-08-31
BRPI0916356B1 (pt) 2022-08-23
CN102105459A (zh) 2011-06-22
ATE557015T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
HK1157337A1 (xx)
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
TW200510385A (en) Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación
UA100390C2 (xx) ПОХІДНА ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОР ПРОТЕЇНКІНАЗИ B, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ПРОМІЖНІ СПОЛУКИ